User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7794

Interactions with Platform & by Email *

INTERACTIONS

1091

Unique # Participated *

PARTICIPANTS

234

Responses Validated *

VALIDATIONS

44

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Types of Lymphomas.....I-3
Hodgkin’s lymphoma.....I-3
Non-Hodgkin’s lymphoma.....I-3
  
   Global Lymphoma Therapeutics Market to Surge.....II-1
Europe Leads the Global Lymphoma Therapeutics Market.....II-1
Lymphoma Incidence and Mortality Rates On the Rise.....II-1
1$100
   Incidence of Hodgkin's Lymphoma - High in West Asia.....II-2
Table 1: Age-Standardized Incidence Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart).....II-2

Table 2: Age-Standardized Mortality Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart).....II-2
1$350
   Rituxan’s Dominance - A Major Hurdle to Other Emerging Drugs.....II-3
Huge Unmet Needs to Drive Product Innovation.....II-3
Radioimmunotherapy Drug Penetration Continues to Remain Lower.....II-3
1$100
   Table 3: Monthly Cost of Select Non-Hodgkin’s Lymphoma Treatment (2009).....II-4
Sales of Zevalin to Gain Momentum.....II-4
1$350
   Combination Drugs – A Potential Winning Option for Manufacturers.....II-5
Existing Drugs for Lymphoma.....II-5
Select Approved Drugs In Lymphoma Treatment.....II-5
1$100
   Rituxan – the Undisputed Leader in NHL Drugs.....II-6
Key Indications for Rituxan in the US.....II-6
Zevalin (Biogen Idec).....II-6
Overview.....II-6
1$100
   Administration.....II-7
Efficacy.....II-7
Bexxar (GlaxoSmithKline).....II-7
1$100
   Ribomustin®/Treanda®.....II-8
Pipeline Drugs for Lymphoma.....II-8
Select Pipeline Drugs In Lymphoma Treatment.....II-8
1$100
   Select Vaccines In Pipeline for Lymphoma Treatment.....II-91$100
   Pixantrone (Cell Therapeutics).....II-10
Affinitor (Novartis).....II-10
SGN-35 (Seattle Genetics).....II-10
SAR3419 (ImmunoGen, Inc.).....II-10
1$100
   Overview of Treatment Options for NHL.....II-11
Chemotherapy.....II-11
Radiotherapy.....II-11
1$100
   Antibody Therapy.....II-12
Stem Cell Transplants.....II-12
1$100
   Lymphomas.....II-13
Types of Lymphomas.....II-13
Hodgkin’s lymphoma.....II-13
Non-Hodgkin’s lymphoma.....II-13
Classification – Based on Type of Cells Involved.....II-13
1$100
   Hodgkin’s Lymphomas.....II-14
Natural Killer (NK) and Mature T cell Neoplasms.....II-14
Mature B cell Neoplasms.....II-14
1$100
   Classification - Based on Disease Progression.....II-15
Indolent Lymphomas.....II-15
Aggressive Lymphomas.....II-15
Background.....II-15
1$100
   Signs and Symptoms.....II-16
Etiology and Risk Factors.....II-16
Immunological functions.....II-16
Infections.....II-16
1$100
   Lifestyle Factors.....II-17
Diagnosis of Lymphoma.....II-17
Prognosis.....II-17
Treatment of Lymphoma.....II-17
2$125
   Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL.....II-19
Allos Obtains FDA Approval for FOLOTYN™.....II-19
Spectrum Receives FDA Approval for Zevalin® Expanded Label.....II-19
1$100
   Genzyme Receives European Commission Approval for Mozobil®.....II-20
Cephalon Obtains FDA Approval for TREANDA for Treating Indolent NHL.....II-20
GSK Receives European Approval for Atriance®.....II-20
1$100
   Celgene to Acquire Gloucester Pharmaceuticals.....II-21
Scientists at Cornell Discover New Molecular Mechanism for Treating NHL.....II-21
1$100
   CTI Seeks Orphan Drug Designation for Pixantrone in Europe.....II-22
FDA's ODAC Recommends Romidepsin’s Approval.....II-22
Seattle Genetics Completes Enrollment for Brentuximab Vedotin.....II-22
1$100
   InNexus Biotechnology to Initiate Business Development for DXL625.....II-23
Allos Therapeutics Introduces focusonptcl.com.....II-23
InNexus Inks Letter of Intent with Genhelix.....II-23
Pfizer Acquires Wyeth.....II-23
LLS and FORMA Join Hands to Accelerate Development of New Therapies.....II-23
1$100
   Biovest and idis Ink Partnership Deal for Distribution of BiovaxID®.....II-24
SymBio Pharmaceuticals Signs a License Agreement with Eisai.....II-24
1$100
   Seattle Genetics Receives Fast Track Designation from FDA for SGN-35.....II-25
Spectrum Acquires ZEVALIN® from RIT Oncology.....II-25
EpiCept Announces Crinobulin as Generic Name for EPC2407.....II-25
CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals.....II-25
1$100
   Allos Receives Orphan Drug Designation for Pralatrexate from FDA.....II-26
Takeda Acquires Millennium Pharmaceuticals.....II-26
1$100
   Allos Therapeutics, Inc. (US).....II-27
Astellas Pharma US, Inc. (US).....II-27
Biogen Idec (US).....II-27
1$100
   Biolex Therapeutics, Inc. (US).....II-28
Biovest International, Inc. (US).....II-28
Cell Therapeutics, Inc. (US).....II-28
1$100
   Cephalon, Inc. (US).....II-29
Chugai Pharmaceutical Co., Ltd. (Japan).....II-29
1$100
   Cyclacel Pharmaceuticals, Inc. (US).....II-30
Eisai, Ltd. (Japan).....II-30
EpiCept Corp. (US).....II-30
F. Hoffmann-la Roche Ltd. (Switzerland).....II-30
1$100
   Genentech, Inc. (US).....II-31
Genmab (Denmark).....II-31
1$100
   Genitope Corp. (US).....II-32
Genzyme Corporation (US).....II-32
GlaxoSmithKline, Plc. (UK).....II-32
1$100
   Hana Biosciences, Inc. (US).....II-33
ImmunoGen, Inc. (US).....II-33
InNexus Biotechnology, Inc. (Canada).....II-33
1$100
   Millennium Pharmaceuticals, Inc. (US).....II-341$100
   Table 4: World Recent Past, Current & Future Analysis for Lymphoma Drugs Market by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-351$350
   Table 5: World 10-year Perspective for Lymphoma Drugs Market by Geographic Region - Percentage Breakdown of Value Sales for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-361$350
   A. Market Analysis.....III-1
Rising Incidence of Lymphomas to Fuel Market Growth.....III-1
Mortality Rate Slips.....III-1
Lymphomas – The Third Leading Cause of Cancer in Children.....III-1
1$75
   Table 6: Percentage Breakdown of Cancer Incidence in US Children by Type (2006) (includes corresponding Graph/Chart).....III-2
White Children – Most Susceptible to Lymphomas.....III-2
Table 7: Incidence of Lymphoma in US Children in 2006 (includes corresponding Graph/Chart).....III-2
1$200
   Lymphoma Fact Sheet.....III-3
Incidence Rate Rises in Afro-Americans.....III-3
Table 8: US Lymphoma Incidence Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart).....III-3
1$200
   Table 9: US Lymphoma Incidence Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart).....III-4

Table 10: US Lymphoma Mortality Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart).....III-4
1$200
   Table 11: US Lymphoma Mortality Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart).....III-5
Select Players in the Region.....III-5
6$200
   New Drug Approvals.....III-111$75
   Strategic Corporate Developments.....III-125$225
   B. Market Analytics.....III-17
Table 12: US Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-17
1$200
   A. Market Analysis.....III-18
Europe – The Largest Market for Lymphoma Therapeutics Worldwide.....III-18
Incidence of NHL Continues to Climb.....III-18
Table 13: Annual Incidence of Non-Hodgkin’s Lymphomas in Europe: 2003-2010 (includes corresponding Graph/Chart).....III-18
1$200
   Table 14: Incidence Rates of Key Types of Non-Hodgkin’s Lymphomas in Europe: 2006 (includes corresponding Graph/Chart).....III-19
Immunotherapeutic Drugs Dominate the Market.....III-19
1$200
   New Drugs to Transform Non-Hodgkin's Lymphoma Market.....III-20
Restraining Forces Loom Large Over New Drugs.....III-20
An Overview of Lymphomas in United Kingdom.....III-20
1$75
   Table 15: Hodgkin’s Lymphoma Incidence in UK: 2006 (includes corresponding Graph/Chart).....III-21

Table 16: Hodgkin’s Lymphoma Incidence in UK by Gender (2006): Percentage Breakdown by Age Group (includes corresponding Graph/Chart).....III-21
1$200
   Select Players in the Region.....III-221$75
   New Drug Approvals.....III-231$75
   Strategic Corporate Developments.....III-241$75
   B. Market Analytics.....III-25
Table 17: European Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-25
1$200
   A. Market Analysis.....III-26
Rest of World Lymphoma Therapeutics Market to Witness Rapid Growth.....III-26
Select Players in the Region.....III-26
1$75
   Strategic Corporate Developments.....III-271$75
   B. Market Analytics.....III-28
Table 18: Rest of World Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-28
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com